International Isotopes receives FDA nod for I-131

By staff writers

February 11, 2020 -- Radioisotope manufacturer International Isotopes received clearance from the U.S. Food and Drug Administration (FDA) for use of its sodium iodide-131 (I-131) radiopharmaceutical to treat hyperthyroidism and thyroid carcinomas.

International Isotopes plans to launch I-131 for commercial distribution soon and hopes to use its approval as a springboard to advance development for other products.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking